Genevieve Nelson
Psychiatric/Mental Health · Davenport, IANPI 1437238110
Payments from drug & device makers
Across 116 payments — averaging $19.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$379
- Teva Pharmaceuticals USA, Inc.$329
- AbbVie$280
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$252
- Alkermes, Inc.$180
- Johnson & Johnson$121
- plus $772 from 14 others
What the payments were for
- Food & beverage$2,16794%
- Education$1476%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 13 | $379 |
| Teva Pharmaceuticals USA, Inc. | 13 | $329 |
| AbbVie | 19 | $280 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 12 | $252 |
| Alkermes, Inc. | 10 | $180 |
| Johnson & Johnson | 6 | $121 |
| Indivior Inc. | 5 | $96 |
| Corium, LLC | 6 | $95 |
| Lundbeck LLC | 5 | $87 |
| E.r. Squibb & Sons, L.L.C. | 4 | $83 |
| Harmony Biosciences LLC | 4 | $71 |
| Axsome Therapeutics, Inc. | 3 | $70 |
| Vanda Pharmaceuticals Inc. | 3 | $55 |
| Idorsia Pharmaceuticals US Inc | 3 | $51 |
| Neurocrine Biosciences, Inc. | 3 | $43 |
| Almatica Pharma LLC | 2 | $39 |
| Supernus Pharmaceuticals, Inc. | 2 | $36 |
| Merck | 1 | $17 |
| Biogen | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,313 in reported general payments places this provider in the 75th percentile of 443 psychiatric/mental health providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 78 | $662,506 |
| Abilify MaintenaAripiprazole | 53 | $153,248 |
| AustedoDeutetrabenazine | 12 | $118,572 |
| Invega SustennaPaliperidone Palmitate | 41 | $117,592 |
| CaplytaLumateperone Tosylate | 60 | $99,871 |
| RexultiBrexpiprazole | 50 | $73,569 |
| Wellbutrin XlBupropion Hcl | 13 | $53,616 |
| AristadaAripiprazole Lauroxil | 19 | $49,993 |
| BelsomraSuvorexant | 90 | $40,866 |
| Clozapine | 221 | $21,767 |
| VyvanseLisdexamfetamine Dimesylate | 56 | $21,240 |
| TrintellixVortioxetine Hydrobromide | 43 | $20,584 |
| Aripiprazole | 351 | $19,797 |
| Lurasidone Hcl | 75 | $19,207 |
| Paliperidone ErPaliperidone | 33 | $16,022 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $43 | $662,50678 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $379 | $226,817103 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $329 | $118,57212 claims |
| Johnson & JohnsonInvega Sustenna | $121 | $117,59241 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $252 | $99,87160 claims |
| Alkermes, Inc.Aristada | $180 | $49,99319 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse, Trintellix | $14 | $41,82499 claims |
| MerckBelsomra | $17 | $40,86690 claims |
| Axsome Therapeutics, Inc.Auvelity | $70 | $14,32215 claims |
| Almatica Pharma LLCSertraline Hcl | $39 | $5,975635 claims |
| Supernus Pharmaceuticals, Inc.Qelbree | $36 | $4,52115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 443 psychiatric/mental health providers in Iowa.
Other psychiatric/mental health in Davenport
- Daniel WesemannDavenport$15K
- Stacy RothDavenport$4K
- Tarrah HollidayAtlantic$421K
- Kelsie SwisherParkersburg$235K
- Jennifer BradleyCedar Rapids$66K
- Kama AusbornWaterloo$64K
- Quentin ChambersDes Moines$40K
- Tenaea JeppesonFort Dodge$38K
- Jennifer WittmanCoralville$25K
- Amy MorinCedar Rapids$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.